Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers
Anca Apavaloaei, Leslie Hesnard, Marie‐Pierre Hardy, Basma Benabdallah, Grégory Ehx, Catherine Thériault, Jean‐Philippe Laverdure, Chantal Durette, Joël Lanoix, Mathieu Courcelles, Nandita Noronha, Kapil Dev Chauhan, Sébastien Lemieux, Christian Beauséjour, Mick Bhatia, Pierre Thibault, Claude Perreault
Abstract
Previous reports showed that mouse vaccination with pluripotent stem cells (PSCs) induces durable anti-tumor immune responses via T cell recognition of some elusive oncofetal epitopes. We characterize the MHC I-associated peptide (MAP) repertoire of human induced PSCs (iPSCs) using proteogenomics. Our analyses reveal a set of 46 pluripotency-associated MAPs (paMAPs) absent from the transcriptome of normal tissues and adult stem cells but expressed in PSCs and multiple adult cancers. These paMAPs derive from coding and allegedly non-coding (48%) transcripts involved in pluripotency maintenance, and their expression in The Cancer Genome Atlas samples correlates with source gene hypomethylation and genomic aberrations common across cancer types. We find that several of these paMAPs were immunogenic. However, paMAP expression in tumors coincides with activation of pathways instrumental in immune evasion (WNT, TGF-β, and CDK4/6). We propose that currently available inhibitors of these pathways could synergize with immune targeting of paMAPs for the treatment of poorly differentiated cancers.